VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy. The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
IPO Year: 2021
Exchange: NASDAQ
Website: vectivbio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/13/2022 | $18.00 | Buy | Jefferies |
| 7/1/2022 | $23.00 | Overweight | Piper Sandler |
EFFECT - VectivBio Holding AG (0001836379) (Filer)
EFFECT - VectivBio Holding AG (0001836379) (Filer)
EFFECT - VectivBio Holding AG (0001836379) (Filer)
POS AM - VectivBio Holding AG (0001836379) (Filer)
POS AM - VectivBio Holding AG (0001836379) (Filer)
POS AM - VectivBio Holding AG (0001836379) (Filer)
S-8 POS - VectivBio Holding AG (0001836379) (Filer)
S-8 POS - VectivBio Holding AG (0001836379) (Filer)
6-K - VectivBio Holding AG (0001836379) (Filer)
25 - VectivBio Holding AG (0001836379) (Filer)